Listing of the STXHLT ETF and the Scheme Referencing the Stoxx Global Breakthrough Healthcare Index SATRIX COLLECTIVE INVESTMENT SCHEME SATRIX HEALTHCARE INNOVATION FEEDER ETF JSE Code: STXHLT ISIN: ZAE000310496 ("Satrix Healthcare Innovation" or the "Portfolio") A portfolio in the Satrix Collective Investment Scheme, registered as such in terms of the Collective Investment Schemes Control Act, 45 of 2002. LISTING OF THE SATRIX HEALTHCARE INNOVATION FEEDER ETF AND THE SCHEME REFERENCING THE STOXX GLOBAL BREAKTHROUGH HEALTHCARE INDEX ON THE MAIN BOARD OF THE JSE LIMITED (“JSE”) IN THE EXCHANGE TRADED FUND SECTOR. This announcement is issued for information purposes only relating to the listing of the portfolio on the JSE. 1. Introduction Satrix Healthcare Innovation participatory interests provide the investors exposure to companies that are focused on innovation within global healthcare services, across both developed and emerging markets. 2. Listing approval Approval for the listing of the participatory interest in the portfolio was granted by the JSE on 05 May 2022. 3. Summary of the offer 3.1. Issuer Satrix Healthcare Innovation, a portfolio in the Satrix Collective Investment Scheme in Securities, registered in terms of the Collective Investment Schemes Control Act, No 45 of 2002. 3.2. ISIN: ZAE000310496 3.3. Share code: STXHLT 3.4. Long name: Satrix Healthcare Innovation Feeder ETF 3.5. Abbreviated name: SATRIXHLT 3.6. Index Launched in June 2016, the STOXX Global breakthrough Healthcare Index belongs to a defined set of developed and emerging countries, that derive more than 50% of their most recent total annual revenue from sectors linked to the breakthrough healthcare trend are highlighted as potential index components. The index excludes companies that are not compliant with the Sustainalytics Global Standards Screening assessment or are involved in Controversial Weapons and other controversial activities. Moreover, companies that display high ESG Controversy Ratings are also excluded. The index constituents are weighted by the security free-float adjusted market capitalization calculated based on the Foreign Inclusion Factor (FIF) and subject to Foreign Ownership Limits (FOLs). 3.7. Distribution or accounting period The underlying fund reinvests the income from the constituents in the index and therefore does not distribute. 3.8. The ramp up period It is the period during which the manager will procure the acquisition of baskets with the cash proceeds from the initial offer and will be announced at the close of the offer. 4. Salient dates and times 4.1. Opening date of the initial offer at 09:00 on Wednesday, 04 May 2022 4.2. Closing date of the initial offer at 12:00 on Tuesday, 17 May 2022 4.3. Ramp up period in respect of cash subscriptions commences on Wednesday, 18 May 2022 4.4. Settlement of Letters of allocation on Thursday, 19 May 2022 4.5. Publication of announcement on SENS as to the results of the initial offer on Friday, 20 May 2022 4.6. Publication of conversion ratio on Monday, 23 May 2022 4.7 Ramp up period in respect of in specie subscriptions, Wednesday, 25 May 2022 4.8. Listing date at 9:00 on Thursday, 26 May 2022 * One letter of allocation (“LA”) will be issued for every Rand subscription against a subscriber’s CSDP or broker account being debited with the Rand amount. Once the baskets of Index constituents have been acquired, STRATE will convert the LAs to Satrix securities in the CSDP accounts in terms of the conversion ratios that will be published on SENS. 5. Copies of the supplement to the programme memorandum A supplement to the programme memorandum detailing this offer is available on the website of the Satrix Collective Investment Scheme on www.satrix.co.za 05 May 2022 Satrix Managers (RF) Pty Limited JSE Sponsor Vunani Date: 05-05-2022 01:25:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.